Hydroxyurea

Generic Name
Hydroxyurea
Brand Names
Droxia, Hydrea, Siklos, Xromi
Drug Type
Small Molecule
Chemical Formula
CH4N2O2
CAS Number
127-07-1
Unique Ingredient Identifier
X6Q56QN5QC
Background

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Indication

Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
Associated Therapies
Chemoradiotherapy, Radiation Therapy
Clinical Trials
Related News

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

Phase 2
Not yet recruiting
Conditions
Sickle Cell Disease
Interventions
Drug: Hydroxycarbamid
First Posted Date
2024-08-29
Last Posted Date
2024-08-29
Lead Sponsor
Theravia
Target Recruit Count
50
Registration Number
NCT06578507
Locations
🇬🇫

Centre hospitalier de Cayenne, Cayenne, French Guiana

🇫🇷

Centre Hospitalier Intercommunal Créteil, Créteil, France

🇫🇷

Hôpital Bicêtre, Le Kremlin-Bicêtre, France

and more 1 locations

Stroke Prevention in Nigeria 2 Trial

Phase 4
Recruiting
Conditions
Sickle Cell Disease
Stroke
Interventions
Drug: Hydroxyurea
First Posted Date
2024-07-29
Last Posted Date
2024-08-29
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
220
Registration Number
NCT06526117
Locations
🇳🇬

Aminu Kano Teaching Hospital, Kano, Nigeria

🇳🇬

Murtala Muhammad Specialist Hospital, Kano, Nigeria

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

First Posted Date
2024-06-13
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
300
Registration Number
NCT06456346
Locations
🇯🇵

Fujita Health University ( Site 0613), Toyoake, Aichi, Japan

🇯🇵

Ehime University Hospital ( Site 0612), Toon, Ehime, Japan

🇯🇵

Hokkaido University Hospital ( Site 0601), Sapporo, Hokkaido, Japan

and more 58 locations

Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.

Phase 2
Completed
Conditions
Beta-Thalassemia
Interventions
Drug: Thalidomide 100mg
Drug: Hydroxyurea
First Posted Date
2024-02-02
Last Posted Date
2024-03-12
Lead Sponsor
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Target Recruit Count
24
Registration Number
NCT06239389
Locations
🇵🇰

National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Sindh, Pakistan

Realizing Effectiveness Across Continents With Hydroxyurea

Phase 2
Recruiting
Conditions
Children
Sickle Cell Disease
Interventions
Drug: Hydroxyurea
First Posted Date
2023-12-14
Last Posted Date
2023-12-14
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
822
Registration Number
NCT06171217
Locations
🇺🇬

Mbale Regional Hospital, Mbale, Uganda

🇰🇪

KEMRI/Wellcome Trust Research, Kilifi, Kenya

🇨🇩

Centre Hospitalier Monkole, Kinshasa, Congo, The Democratic Republic of the

and more 1 locations

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Phase 3
Recruiting
Conditions
Polycythemia Vera
Interventions
Drug: Hydroxyurea
Drug: Givinostat
First Posted Date
2023-10-23
Last Posted Date
2024-12-06
Lead Sponsor
Italfarmaco
Target Recruit Count
220
Registration Number
NCT06093672
Locations
🇺🇸

VA Puget Sound Health Care System - NAVREF - PPDS, Seattle, Washington, United States

🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 73 locations

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

Phase 2
Recruiting
Conditions
Sickle Cell Disease
Interventions
Drug: Etavopivat
Drug: Hydroxyurea
First Posted Date
2023-07-20
Last Posted Date
2024-10-29
Lead Sponsor
Forma Therapeutics, Inc.
Target Recruit Count
46
Registration Number
NCT05953584
Locations
🇮🇳

All India Institute of Medical Sciences (AIIMS), Raipur, Raipur, Chhattisgarh, India

🇮🇳

All India Institute of Medical Sciences-Delhi, Delhi, India

🇮🇳

Nirmal Hospital Pvt. Ltd., Gujarat, India

and more 6 locations

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

Phase 4
Recruiting
Conditions
Polycythemia Vera
Interventions
Drug: Hydroxyurea
First Posted Date
2023-05-10
Last Posted Date
2024-11-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
300
Registration Number
NCT05853458
Locations
🇩🇪

Novartis Investigative Site, Wuerselen, Germany

Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa

Not Applicable
Completed
Conditions
Sickle-Cell Anaemia
Interventions
Drug: Hydroxyurea
First Posted Date
2023-01-12
Last Posted Date
2023-01-12
Lead Sponsor
University of Kinshasa
Target Recruit Count
166
Registration Number
NCT05681598
Locations
🇨🇩

University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the

Alternative Dosing And Prevention of Transfusions (ADAPT)

Early Phase 1
Recruiting
Conditions
Sickle Cell Disease
Interventions
Drug: Hydroxyurea
First Posted Date
2022-12-22
Last Posted Date
2024-01-10
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
100
Registration Number
NCT05662098
Locations
🇺🇬

Jinja Regional Referral Hospital (JRRH), Department of Paediatrics, Sickle Cell Clinic, Jinja, Uganda

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy